Skin disease linked to gadolinium prompts warning
The risk that some patients have for developing a debilitating, life-threatening skin disease linked to the administration of gadolinium calls for close scrutiny of kidney function or even a higher threshold of glomular filtration rate.
The risk that some patients have for developing a debilitating, life-threatening skin disease linked to the administration of gadolinium calls for close scrutiny of kidney function or even a higher threshold of glomular filtration rate.
Around 400 cases of nephrogenic systemic fibrosis (NSF) have been idenitified worldwide, and most are related to the administration of gadodiamide (Omniscan, GE Healthcare) in patients with moderate to end-stage kidney disease, according to Prof. Henrik Thomsen, a radiologist at Copenhagen University Hospital in Denmark.
Patients with a GFR of < 30 mL/min and those on dialysis are at risk, Thomsen said. There also have been reports of patients with a serum creatinine below 2 mg/dL after gadodiamide administration, suggesting that the threshold could be set higher at < 60 mL/min.
GE Healthcare has posted warnings about gadodiamide on its website.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
